Ly, K. Ina
Vakulenko-Lagun, Bella
Emblem, Kyrre E.
Ou, Yangming http://orcid.org/0000-0002-7726-6208
Da, Xiao
Betensky, Rebecca A.
Kalpathy-Cramer, Jayashree http://orcid.org/0000-0001-8906-9618
Duda, Dan G.
Jain, Rakesh K.
Chi, Andrew S.
Plotkin, Scott R.
Batchelor, Tracy T.
Sorensen, Gregory
Rosen, Bruce R.
Gerstner, Elizabeth R.
Article History
Received: 16 April 2018
Accepted: 24 October 2018
First Online: 20 November 2018
Change Date: 14 June 2019
Change Type: Correction
Change Details: A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.
Competing Interests
: R.K.J. received consultant fees from Enlight, Ophthotech, SPARC, and SynDevRx. R.K.J. owns equity in Enlight, Ophthotech, SynDevRx, and XTuit and serves on the Board of Directors of XTuit and the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, the Tekla Healthcare Opportunities Fund, and the Tekla World Healthcare Fund. D.G.D. is a paid consultant for Tilos, Bayer, and BMS and received research support from Bayer, Merrimack, BMS, Leap Tx, and Exelixis. K.E.E. owns intellectual property rights in NordicNeuroLab AS. G.S. has equity in and serves on the board of directors of IMRIS. T.T.B. has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck & Co., Inc., NXDC, Amgen, UpToDate, Inc., and Jiahui Health. All other authors declare no potential conflict of interest.